Advertisement

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement

May

02

Today In Oncology

FDA Approves Vepdegestrant for ER-HER2 ESR1 Advanced Breast Cancer

Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy

Association of Body Size and Bladder Cancer Risk

5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Can PFAS Exposure Raise ALL Risk?

Advertisement

© 2026 HSP News Service, L.L.C.